<DOC>
	<DOC>NCT02132572</DOC>
	<brief_summary>Retrospective multi-center, post-marketing study to evaluate the incidence and etiology of reoperations with Allergan Natrelle® Breast Implants in primary augmentation (RANBI)</brief_summary>
	<brief_title>Retrospective Study of Incidence and Etiology of Reoperation After Primary Augmentation With Natrelle® Breast Implants</brief_title>
	<detailed_description />
	<criteria>Primary breast augmentation (either bilateral or unilateral) operated on by the investigating surgeon with an inframammary approach 410 cohesive BIOCELL™ textured device (Truform 2 &amp; 3 only) has been implanted Primary breast augmentation 3 to 10 years prior to data collection Submuscular/dual plane or subglandular implant placement Breast augmentation for Poland Syndrome or amastia Breast reconstruction following mastectomy Revision or secondary breast reconstruction Non 410 device at initial breast augmentation Women subsequently diagnosed with fibrocystic disease considered to be premalignant Procedures of the breast not related to the primary breast augmentation (e.g. excision of skin lesions) Axillary or periareolar approach Glandular mastopexy augmentation (skin excision only)</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>